Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.
analytical validation
circulating tumor DNA
molecular residual disease
tumor-informed assay
whole genome sequencing
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
medline:
18
3
2024
pubmed:
14
3
2024
entrez:
14
3
2024
Statut:
epublish
Résumé
We describe the analytical validation of NeXT Personal
Identifiants
pubmed: 38484152
pii: 28565
doi: 10.18632/oncotarget.28565
pmc: PMC10939476
doi:
Substances chimiques
Circulating Tumor DNA
0
DNA, Neoplasm
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
200-218Références
Genome Med. 2019 Apr 19;11(1):22
pubmed: 31003596
Gastroenterology. 2020 Feb;158(3):494-505.e6
pubmed: 31711920
PLoS Med. 2021 May 3;18(5):e1003620
pubmed: 33939694
JAMA Netw Open. 2022 Mar 1;5(3):e221093
pubmed: 35258578
Nature. 2017 Apr 26;545(7655):446-451
pubmed: 28445469
Ann Oncol. 2019 May 1;30(5):804-814
pubmed: 30838379
JCO Precis Oncol. 2020 Nov;4:1246-1262
pubmed: 35050782
Cancer Discov. 2021 Dec 1;11(12):2968-2986
pubmed: 34785539
Br J Cancer. 2021 Jan;124(2):345-358
pubmed: 32968207
Clin Colorectal Cancer. 2023 Mar;22(1):53-58
pubmed: 36567192
Ann Oncol. 2021 Apr;32(4):522-532
pubmed: 33359547
Cancers (Basel). 2021 Nov 14;13(22):
pubmed: 34830853
Nat Med. 2023 Apr;29(4):859-868
pubmed: 36928816
Cancer Discov. 2017 Dec;7(12):1394-1403
pubmed: 28899864
Nature. 2023 Apr;616(7957):553-562
pubmed: 37055640
PLoS One. 2020 Sep 25;15(9):e0237802
pubmed: 32976510
PLoS Med. 2016 Dec 20;13(12):e1002198
pubmed: 27997533
Sci Transl Med. 2016 Jul 6;8(346):346ra92
pubmed: 27384348
JCO Precis Oncol. 2022 Mar;6:e2100181
pubmed: 35263168
Front Oncol. 2023 Jan 26;12:1055968
pubmed: 36776372
Nat Cancer. 2020 Sep;1(9):873-881
pubmed: 35121950
Mol Diagn Ther. 2023 Nov;27(6):753-768
pubmed: 37632661
N Engl J Med. 2022 Jun 16;386(24):2261-2272
pubmed: 35657320
Ann Oncol. 2022 May;33(5):500-510
pubmed: 35306155
Cancers (Basel). 2021 Jul 26;13(15):
pubmed: 34359659
Mol Cancer Ther. 2019 Jan;18(1):196-203
pubmed: 30301865
Nat Med. 2023 Jan;29(1):127-134
pubmed: 36646802
Eur Urol Oncol. 2024 Feb;7(1):44-52
pubmed: 37330413
JCO Precis Oncol. 2023 Apr;7:e2200543
pubmed: 37027813
Ann Oncol. 2015 Aug;26(8):1715-22
pubmed: 25851626
J Clin Oncol. 2022 Aug 1;40(22):2408-2419
pubmed: 35658506
Clin Cancer Res. 2020 Apr 15;26(8):1877-1885
pubmed: 31941831
JAMA Oncol. 2019 Oct 1;5(10):1473-1478
pubmed: 31369045
Sci Adv. 2022 Jan 28;8(4):eabi8618
pubmed: 35080978
J Thorac Oncol. 2018 Jan;13(1):112-123
pubmed: 28951314
J Clin Invest. 2022 Jun 15;132(12):
pubmed: 35703177
Clin Cancer Res. 2019 Jul 15;25(14):4255-4263
pubmed: 30992300
Cancers (Basel). 2021 Jan 19;13(2):
pubmed: 33477814
NPJ Precis Oncol. 2021 Jul 2;5(1):63
pubmed: 34215841
Med. 2021 Dec 10;2(12):1292-1313
pubmed: 35590147
PLoS One. 2015 Dec 30;10(12):e0145754
pubmed: 26717006
Clin Cancer Res. 2020 Jun 1;26(11):2556-2564
pubmed: 32170028
Nat Commun. 2015 Jul 07;6:7686
pubmed: 26154128